Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nuvation Bio (NUVB) Total Non-Current Liabilities (2023 - 2025)

Nuvation Bio (NUVB) has disclosed Total Non-Current Liabilities for 3 consecutive years, with $289.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Non-Current Liabilities rose 286.58% to $289.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $289.1 million, a 286.58% increase, with the full-year FY2025 number at $289.1 million, up 286.58% from a year prior.
  • Total Non-Current Liabilities was $289.1 million for Q4 2025 at Nuvation Bio, up from $273.9 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $289.1 million in Q4 2025 to a low of $15.3 million in Q1 2023.
  • A 3-year average of $99.4 million and a median of $64.6 million in 2024 define the central range for Total Non-Current Liabilities.
  • Biggest YoY gain for Total Non-Current Liabilities was 367.14% in 2024; the steepest drop was 13.04% in 2024.
  • Nuvation Bio's Total Non-Current Liabilities stood at $16.0 million in 2023, then surged by 367.14% to $74.8 million in 2024, then skyrocketed by 286.58% to $289.1 million in 2025.
  • Per Business Quant, the three most recent readings for NUVB's Total Non-Current Liabilities are $289.1 million (Q4 2025), $273.9 million (Q3 2025), and $272.0 million (Q2 2025).